Compare ERC & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | QTTB |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.7M | 265.2M |
| IPO Year | N/A | 2018 |
| Metric | ERC | QTTB |
|---|---|---|
| Price | $8.31 | $8.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 90.6K | ★ 341.5K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.31 | $1.91 |
| 52 Week High | $9.56 | $23.57 |
| Indicator | ERC | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 46.47 |
| Support Level | N/A | $8.23 |
| Resistance Level | $9.20 | $9.41 |
| Average True Range (ATR) | 0.11 | 0.54 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 7.14 | 39.29 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).